BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8009 related articles for article (PubMed ID: 23174497)

  • 1. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
    Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
    Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.
    Anderson S; Bloom KJ; Vallera DU; Rueschoff J; Meldrum C; Schilling R; Kovach B; Lee JR; Ochoa P; Langland R; Halait H; Lawrence HJ; Dugan MC
    Arch Pathol Lab Med; 2012 Nov; 136(11):1385-91. PubMed ID: 22332713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.
    Halait H; Demartin K; Shah S; Soviero S; Langland R; Cheng S; Hillman G; Wu L; Lawrence HJ
    Diagn Mol Pathol; 2012 Mar; 21(1):1-8. PubMed ID: 22306669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.
    Ihle MA; Fassunke J; König K; Grünewald I; Schlaak M; Kreuzberg N; Tietze L; Schildhaus HU; Büttner R; Merkelbach-Bruse S
    BMC Cancer; 2014 Jan; 14():13. PubMed ID: 24410877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas.
    Lade-Keller J; Rømer KM; Guldberg P; Riber-Hansen R; Hansen LL; Steiniche T; Hager H; Kristensen LS
    J Mol Diagn; 2013 Jan; 15(1):70-80. PubMed ID: 23159593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib.
    Lopez-Rios F; Angulo B; Gomez B; Mair D; Martinez R; Conde E; Shieh F; Vaks J; Langland R; Lawrence HJ; de Castro DG
    PLoS One; 2013; 8(1):e53733. PubMed ID: 23326492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays.
    Qu K; Pan Q; Zhang X; Rodriguez L; Zhang K; Li H; Ho A; Sanders H; Sferruzza A; Cheng SM; Nguyen D; Jones D; Waldman F
    J Mol Diagn; 2013 Nov; 15(6):790-5. PubMed ID: 23994118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma.
    Franczak C; Salleron J; Dubois C; Filhine-Trésarrieu P; Leroux A; Merlin JL; Harlé A
    Mol Diagn Ther; 2017 Apr; 21(2):209-216. PubMed ID: 28130756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
    Bisschop C; Ter Elst A; Bosman LJ; Platteel I; Jalving M; van den Berg A; Diepstra A; van Hemel B; Diercks GFH; Hospers GAP; Schuuring E
    Melanoma Res; 2018 Apr; 28(2):96-104. PubMed ID: 29232304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.
    Jurkowska M; Gos A; Ptaszyński K; Michej W; Tysarowski A; Zub R; Siedlecki JA; Rutkowski P
    Int J Clin Exp Pathol; 2015; 8(7):8487-93. PubMed ID: 26339422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma.
    Melchior L; Grauslund M; Bellosillo B; Montagut C; Torres E; Moragón E; Micalessi I; Frans J; Noten V; Bourgain C; Vriesema R; van der Geize R; Cokelaere K; Vercooren N; Crul K; Rüdiger T; Buchmüller D; Reijans M; Jans C
    Exp Mol Pathol; 2015 Dec; 99(3):485-91. PubMed ID: 26407762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A HRM assay for identification of low level BRAF V600E and V600K mutations using the CADMA principle in FFPE specimens.
    Huebner C; Weber R; Lloydd R
    Pathology; 2017 Dec; 49(7):776-783. PubMed ID: 29100713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.
    Colomba E; Hélias-Rodzewicz Z; Von Deimling A; Marin C; Terrones N; Pechaud D; Surel S; Côté JF; Peschaud F; Capper D; Blons H; Zimmermann U; Clerici T; Saiag P; Emile JF
    J Mol Diagn; 2013 Jan; 15(1):94-100. PubMed ID: 23159108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitive allele-specific real-time PCR test for mutations in BRAF codon V600 in skin melanoma.
    Pisareva E; Gutkina N; Kovalenko S; Kuehnapfel S; Hartmann A; Heinzerling L; Schneider-Stock R; Lyubchenko L; Shamanin VA
    Melanoma Res; 2014 Aug; 24(4):322-31. PubMed ID: 24922189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
    Fisher KE; Cohen C; Siddiqui MT; Palma JF; Lipford EH; Longshore JW
    Hum Pathol; 2014 Nov; 45(11):2281-93. PubMed ID: 25228337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies.
    Lamy PJ; Castan F; Lozano N; Montélion C; Audran P; Bibeau F; Roques S; Montels F; Laberenne AC
    J Mol Diagn; 2015 Jul; 17(4):366-73. PubMed ID: 25952101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
    Kim A; Cohen MS
    Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 401.